Novo Nordisk's Obesity Drug Success Needs New Products

Novo Nordisk’s blockbuster obesity drugs are driving massive growth, but the company needs new blockbusters to sustain momentum beyond current successes.

What's Hot

Attackers Drain $20M XRP From 6,678 Wallets in Six Waves

Bitcoin Options Worth $15.6 Billion Expire Friday

Ledger Integrates Private Zcash Balances, Aims to Boost ZEC

Bitcoin ETFs See Record $1B Inflows on Biggest Day

DeFi Development Corp Buys 101,381 SOL For Treasury

Bitget Leads Exchanges with 46 Monthly Proof-of-Reserves Reports

OKX US CEO: Tokenized Stocks Need Equal Shareholder Rights

Whale Demand Assessed for LayerZero’s ZRO $2 Breakout

Coinbase Expands Morpho Loans for Fixed-Rate Bitcoin Borrowing

Hut 8 Acquires Poolin’s Texas Data Centers for $140 Million

Novo Nordisk’s Obesity Drug Success Needs New Products

Attackers Drain $20M XRP From 6,678 Wallets in Six Waves

Bitcoin Options Worth $15.6 Billion Expire Friday

Ledger Integrates Private Zcash Balances, Aims to Boost ZEC

Bitcoin ETFs See Record $1B Inflows on Biggest Day

Attackers Drain $20M XRP From 6,678 Wallets in Six Waves

Bitcoin Options Worth $15.6 Billion Expire Friday

Ledger Integrates Private Zcash Balances, Aims to Boost ZEC

What's Hot

Novo Nordisk’s Obesity Drug Success Needs New Products

Related Posts